Great points @AmandaNizamMD Lenvatinib seems to provide much of the benefit. Belzutifan alone produces durable responses in a minority. Unclear to me why we should give up tolerability of belzutifan and mTORi as a MOA for ccRCC
LITESPARK-011 showed improved PFS with len + bel vs cabo in the mRCC post-ICI setting. No OS benefit yet.View quoted post on X
Prof. Bernard Escudier with an important question: how much of the benefit is due to len itself vs addition of bel?
Similarly, we saw improvement in PFS with post-ICI len + ev vs cabo in the multicenter Ph 2 LenCabo trial from @OncHahn presented at ESMO 2025.
Sequencing in mRCC will shift as the adjuvant RCC space evolves. Congratulations to @DrDanielHeng!
@PavlosMsaouel @ChadTangMD @NazliDizman @OncoAlert @PBarataMD @ADESAIONCMD @montypal @scocmem @nataliagandur
